People taking GLP-1 drugs had a 14% lower risk of experiencing a major heart event compared to those on a placebo. The benefits extended across the board: fewer deaths overall, fewer non-fatal heart ...

On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from ...

WASHINGTON -- GLP-1 receptor agonist use for weight loss early in pregnancy was associated with a lower likelihood that ...

Wegovy pill prescriptions have now topped 2 million since January, including 1.3 million during Q1 alone. ・CEO Mike Doustdar said that Wegovy is “the most efficacious GLP-1 tablet” and is already used ...

President Trump announced the popular GLP-1 weight loss drugs would soon be more accessible to millions of Americans at a ...

A new GLP-1 weight loss drug called survodutide has shown promising results in a phase 3 clinical trial. The drug, which ...

GLP-1RAs significantly reduce major cardiovascular events, mortality, and other clinically significant complications in ...

After accounting for 14% of all prescription drug spending in 2025, the blockbuster GLP-1 drug class is on track to continue rapid growth and alter pharmaceutical spending trends.  For example, Eli ...

Multiple clinical trials have shown that GLP-1s are safe and effective for patients with obesity, diabetes and cardiovascular ...

GLP-1 receptor agonists, like semaglutide and tirzepatide, are transforming diabetes and weight loss care while revealing surprising gut and immune benefits. Recent studies link them to fewer serious ...

The boost in GLP-1 usage means more people seeing these side effects, which in turn creates new demand for hair care products ...

The majority of weight loss from GLP-1 medication is from fat loss, and not muscle loss, new evidence suggests.